Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study | Zendy

Melissa L. Johnson | Zendy; Byoung Chul Cho | Zendy; Alexander Luft | Zendy; Jorge Alatorre-Alexander | Zendy; Sarayut Lucien Geater | Zendy; К. К. Лактионов | Zendy; SangWe Kim | Zendy; Grygorii Ursol | Zendy; Maen Hussein | Zendy; Farah Louise Lim | Zendy; ChengTa Yang | Zendy; Luiz H. Araujo | Zendy; Haruhiro Saito | Zendy; Niels Reinmuth | Zendy; Xiaojin Shi | Zendy; Lynne Poole | Zendy; Solange Peters | Zendy; Edward B. Garon | Zendy; Tony Mok | Zendy

Open Access

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study

Author(s) -

Melissa L. Johnson,

Byoung Chul Cho,

Alexander Luft,

Jorge Alatorre-Alexander,

Sarayut Lucien Geater,

К. К. Лактионов,

SangWe Kim,

Grygorii Ursol,

Maen Hussein,

Farah Louise Lim,

ChengTa Yang,

Luiz H. Araujo,

Haruhiro Saito,

Niels Reinmuth,

Xiaojin Shi,

Lynne Poole,

Solange Peters,

Edward B. Garon,

Tony Mok

Publication year - 2022

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.22.00975

Subject(s) - durvalumab , tremelimumab , medicine , chemotherapy , hazard ratio , lung cancer , pemetrexed , chemoradiotherapy , oncology , cancer , gastroenterology , immunotherapy , confidence interval , cisplatin , pembrolizumab , ipilimumab

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research